Developing antibodies as potential treatments for fibrosis, rare diseases, and oncology
Lassen Therapeutics is a Frazier-founded company developing antibodies as potential treatments for fibrotic and rare diseases as well as cancer. The company’s lead candidate is LASN-01, a potentially first and best-in-class monoclonal antibody licensed from CSL Limited that targets IL-11 receptor alpha (IL-11R). IL-11 is a central mediator of fibrosis and by blocking IL-11’s interaction with its receptor, LASN-01 may reduce fibrosis and thereby improve outcomes for patients with fibrotic diseases. IL-11 is also a pivotal effector of tumor microenvironment organization and tumor growth, playing a key role as a mediator between cancer and stromal cells.
